The DOI matches its Crossref record; 71 of the 71 references it cites were found in a registry or an index; none of the 15 sources its claims cite is checked for support yet.
Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs
Open accessAbstract
IMPORTANCE: Targeting oncogenic drivers (genomic alterations critical to cancer development and maintenance) has transformed the care of patients with lung adenocarcinomas. The Lung Cancer Mutation Consortium was formed to perform multiplexed assays testing adenocarcinomas of the lung for drivers in 10 genes to enable clinicians to select targeted treatments and enroll patients into clinical trials. OBJECTIVES: To determine the frequency of oncogenic drivers in patients with lung adenocarcinomas and to use the data to select treatments targeting the identified driver(s) and measure survival. DESIGN, SETTING, AND PARTICIPANTS: From 2009 through 2012, 14 sites in the United States enrolled patients with metastatic lung adenocarcinomas and a performance status of 0 through 2 and tested their tumors for 10 drivers. Information was collected on patients, therapies, and survival. INTERVENTIONS: Tumors were tested for 10 oncogenic drivers, and results were used to select matched targeted therapies. MAIN OUTCOMES AND MEASURES: Determination of the frequency of oncogenic drivers, the proportion of patients treated with genotype-directed therapy, and survival. RESULTS: From 2009 through 2012, tumors from 1007 patients were tested for at least 1 gene and 733 for 10 genes (patients with full genotyping). An oncogenic driver was found in 466 of 733 patients (64%). Among these 733 tumors, 182 tumors (25%) had the KRAS driver; sensitizing EGFR, 122 (17%); ALK rearrangements, 57 (8%); other EGFR, 29 (4%); 2 or more genes, 24 (3%); ERBB2 (formerly HER2), 19 (3%); BRAF, 16 (2%); PIK3CA, 6 (<1%); MET amplification, 5 (<1%); NRAS, 5 (<1%); MEK1, 1 (<1%); AKT1, 0. Results were used to select a targeted therapy or trial in 275 of 1007 patients (28%). The median survival was 3.5 years (interquartile range [IQR], 1.96-7.70) for the 260 patients with an oncogenic driver and genotype-directed therapy compared with 2.4 years (IQR, 0.88-6.20) for the 318 patients with any oncogenic driver(s) who did not receive genotype-directed therapy (propensity score-adjusted hazard ratio, 0.69 [95% CI, 0.53-0.9], P = .006). CONCLUSIONS AND RELEVANCE: Actionable drivers were detected in 64% of lung adenocarcinomas. Multiplexed testing aided physicians in selecting therapies. Although individuals with drivers receiving a matched targeted agent lived longer, randomized trials are required to determine if targeting therapy based on oncogenic drivers improves survival. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT01014286.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
0 of 15 cited sources checked · 0 supported · 0 flagged
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“2 or more genes, 24 (3%)”
- Also stated in: § Results · plain
“we found drivers in 2 genes in 24 tumors (3%).”
§ Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs > Abstract > RESULTS
Strength:plain· not yet calibratedn = 24Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passes- Also stated in: § Results · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The 190 patients with an oncogenic driver and treatment with a targeted agent had a median survival of 3.5 years (IQR, 1.96-7.70); the 248 with a driver and no targeted therapy, 2.5 years (P < .001”
§ Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs > Results
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“ERBB2 (formerly HER2), 19 (3%)”
- Also stated in: § Results · plain
“The frequencies of ERBB2 (all exon 20 insertions) were 3% (19 of 733 specimens)”
§ Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs > Abstract > RESULTS
Strength:plain· not yet calibratedn = 733Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passes- Also stated in: § Results · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The median survival was 3.5 years (interquartile range [IQR], 1.96-7.70) for the 260 patients with an oncogenic driver and genotype-directed therapy compared with 2.4 years (IQR, 0.88-6.20) for the 318 patients with any oncogenic driver(s) who did not receive genotype-directed therapy”
- Also stated in: § Results · plain
“The 260 patients with an oncogenic driver and treatment with a targeted agent had a median survival of 3.5 years; the 318 patients with a driver and no targeted therapy, 2.4 years”
§ Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs > Abstract > RESULTS
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes- Also stated in: § Results · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“ALK rearrangements, 57 (8%)”
- Also stated in: § Results · plain
“ALK rearrangements occurred in 57 of 733 specimens (8%).”
§ Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs > Abstract > RESULTS
Strength:plain· not yet calibratedn = 733Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passes- Also stated in: § Results · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“An oncogenic driver was found in 466 of 733 patients (64%).”
- Also stated in: § Results · plain
“Among the 733 specimens tested for all 10 genes, 466 (64% [95% CI, 60%-67%) had an oncogenic driver”
§ Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs > Abstract > RESULTS
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes- Also stated in: § Results · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Among these 733 tumors, 182 tumors (25%) had the KRAS driver”
- Also stated in: § Results · plain
“KRAS mutations were the most frequent, found in 182 of 733 specimens (25%)”
§ Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs > Abstract > RESULTS
Strength:plain· not yet calibratedn = 733Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passes- Also stated in: § Results · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Overall, 28% (95% CI, 24%-30%) of eligible patients and 44% of individuals with drivers detected received a targeted therapy.”
§ Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs > Results
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The frequencies of drivers in the 1007 specimens in which at least 1 gene was assessed are presented in Table 2 and mirror the results with the patients’ tumors with full genotyping.”
§ Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs > Results
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“BRAF, 16 (2%)”
- Also stated in: § Results · plain
“BRAF mutations were 2% (16 of 733 specimens)”
§ Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs > Abstract > RESULTS
Strength:plain· not yet calibratedn = 733Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passes- Also stated in: § Results · plain
- The quote only partly states this claim. 1
- It may state two separate claims as one. 8
- Probably not a substantial claim. 9
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“other EGFR, 29 (4%)”
§ Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs > Abstract > RESULTS
Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesThe quote only partly states this claim.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The LCMC characterized at least 1 gene for 91% (1007 of 1102 patients) of eligible patients with genotyping of all 10 genes in 66% (733 of 1102 patients).”
§ Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs > Discussion
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The median potential follow-up was 2.0 years.”
§ Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs > Results
Strength:plain· not yet calibratedn = 938Tests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The 49 patients with oncogenic drivers other than EGFR or ALK who received a targeted therapy had a median survival of 4.9 years compared with the 678 with (318 patients) or without (360 patients) a driver identified, but not receiving a targeted agent, whose median survivals were 2.4 years with a driver (IQR, 0.88-6.20) and 2.1 years without (P = .14”
§ Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs > Results
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Of the 175 patients (83%) with EGFR(s) mutations, 146 were treated with targeted therapy: 130 with erlotinib alone, and 16 with another EGFR inhibitor alone or in combination.”
§ Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs > Results
Strength:plain· not yet calibratedn = 175Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Patients in the driver + treatment group had a 5% better performance status, a 3-year lower median age, and were more likely to be never smokers (Table 1); factors that could lead to an improved prognosis.”
§ Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs > Discussion
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Multiplexed testing aided physicians in selecting therapies.”
- Also stated in: § Conclusions · plain
“Multiplexed testing aided physicians in selecting therapies and patients for targeted trials.”
§ Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs > Abstract > CONCLUSIONS AND RELEVANCE
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Also stated in: § Conclusions · plain
None of the sources cited for this claim have been checked yet.
In the paper
“Testing for somatic mutations in the epidermal growth factor receptor (EGFR) gene4-6 and rearrangements of the anaplastic lymphoma kinase (ALK) gene7 is now routine.8”
§ Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs > Abstract > CONCLUSIONS AND RELEVANCE
What the sources say
- Not checked yetcites [4] Lynch TJ Bell DW Sordella R Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small cell lung cancer to gefitinib N Engl J Med 2004 350 21 2129 2139 15118073
- Not checked yetcites [5] Paez JG Jänne PA Lee JC EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy Science 2004 304 5676 1497 1500 15118125
- Not checked yetcites [6] Pao W Miller V Zakowski M EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib Proc Natl Acad SciUS A 2004 101 36 13306 13311 PMC516528 15329413
- Not checked yetcites [7] Kwak EL Bang YJ Camidge DR Anaplastic lymphoma kinase inhibition in non-small cell lung cancer N Engl J Med 2010 363 18 1693 1703 20979469 PMC3014291
- Not checked yetcites [8] National Comprehensive Cancer Network NCCN clinical practice guidelines in oncology 2014 http://www.nccn.org/professionals/physician_gls/f_guidelines.asp. Accessed April 21
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Adenocarcinoma was centrally confirmed.”
§ Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs > Methods > Patients
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The LCMC clinical committee chairs reviewed the records of each patient with an oncogenic driver and the targeted agent administered to verify that the treatment was directed against that driver(s) detected in the patient’s tumor.”
§ Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs > Methods > Interventions
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“With the proposed sample size of 1000, the half-width of the 95% CI is less than 5% if the oncogenic driver rate is less than 40%.”
§ Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs > Methods > Statistical Methods
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The decision to recommend a targeted therapy to a patient with a tumor harboring an oncogenic driver was left to the treating physician.”
§ Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs > Methods > Interventions
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The knowledge-based confounding variables adjusted in the propensity model were sex, age at enrollment, performance status, smoking history, stage at diagnosis, prior therapy (surgery, chest radiotherapy, or chemotherapy), and elapsed time from metastatic disease diagnosis to study enrollment (years).”
§ Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs > Methods > Statistical Methods
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Criteria for specimen adequacy were not prespecified.”
§ Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs > Methods > Interventions
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
None of the sources cited for this claim have been checked yet.
In the paper
“The LCMC effort differs from other genomic characterization efforts, like the Cancer Genome Atlas that studied patients with localized disease and obtained tissues exclusively from resection specimens.35-40”
§ Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs > Discussion
What the sources say
- Not checked yetcites [35] Weir BA Woo MS Getz G Characterizing the cancer genome in lung adenocarcinoma Nature 2007 450 7171 893 898 17982442 PMC2538683
- Not checked yetcites [36] Barletta JA Perner S Iafrate AJ Clinical significance of TTF-1 protein expression and TTF-1 gene amplification in lung adenocarcinoma J Cell Mol Med 2009 13 8B 1977 1986 19040416 PMC2830395
- Not checked yetcites [37] Hammerman PS Sos ML Ramos AH Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer Cancer Discov 2011 1 1 78 89 22328973 PMC3274752
- Not checked yetcites [38] Cancer Genome Atlas Research Network Comprehensive genomic characterization of squamous cell lung cancers Nature 2012 489 7417 519 525 [published online September 27, 2012] 22960745 PMC3466113
- Not checked yetcites [39] D’Angelo SP Janjigian YY Ahye N Distinct clinical course of EGFR-mutant resected lung cancers: results of testing of 1118 surgical specimens and effects of adjuvant gefitinib and erlotinib J Thorac Oncol 2012 7 12 1815 1822 23154553
- Not checked yetcites [40] Peifer M Fernández-Cuesta L Sos ML Integrative genome analyses identify key somatic driver mutations of small cell lung cancer Nat Genet 2012 44 10 1104 1110 22941188 PMC4915822
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The LCMC pathologists shared blinded samples, with a positive sample included for all 10 drivers.”
§ Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs > Methods > Interventions
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The multiplexed genotyping platforms made effective use of patient tissue and identified actionable drivers sooner, giving patient’s earlier access to therapies or trials.”
§ Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs > Discussion
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The presence of EGFR mutations defines a specific molecular subgroup of NSCLC (~15% of Caucasian patients with adenocarcinomas) [37, 38] that respond to an EGFR TKI in over 60% of patients (Table 1).”
From A decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): Old successes and future perspectives (2015) · cites this paper as [38]
In the citing paper
“Somatic mutations in the kinase domain of the epidermal growth factor receptor (EGFR) gene are detected in approximately 40% and 17% of lung adenocarcinoma in Asians1 and in Caucasians,2 respectively.”
From Not all epidermal growth factor receptor mutations in lung cancer are created equal: Perspectives for individualized treatment strategy (2016) · cites this paper as [2]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
MET amplification count differs within the full-genotyping results
MajorMET amplification is reported in 5 of the 733 fully genotyped tumors, but the later count assigns MET amplification to 8 double-driver tumors in that group.
“Amplification of MET (MET/ CEP7 >2.2) was found in 5 of 733 patients’ tumors (<1%).”
“In the full genotyping group, we found drivers in 2 genes in 24 tumors (3%). Of these 24 specimens, 20 (83%) included either a mutation in PIK3CA (n = 12) or MET amplification (n = 8).”
Targeted-therapy percentage is overstated
MinorThe reported 275 of 1007 patients is 27.3%, which rounds to 27%, not 28%.
Reported 28 · recomputed 27.308838
“Results were used to select a targeted therapy or trial in 275 of 1007 patients (28%).”
Supplementary figure number conflicts for the exclusion analysis
MinorThe Results attribute the analysis excluding EGFR- and ALK-positive cancers to eFigure 6, whereas the Discussion attributes that analysis to eFigure 4.
“We also recomputed the survival data excluding individuals with EGFR- and ALK-positive cancers. The 49 patients with oncogenic drivers other than EGFR or ALK who received a targeted therapy had a median survival of 4.9 years compared with the 678 with (318 patients) or without (360 patients) a driver identified, but not receiving a targeted agent, whose median survivals were 2.4 years with a driver (IQR, 0.88-6.20) and 2.1 years without (P = .14; eFigure 6 in the Supplement).”
“survival analyses excluding these patients revealed that individuals with other drivers treated with targeted therapies still had an observed 2.5-year improvement in median survival over those who did not receive targeted therapy (eFigure 4 in the Supplement).”
Citations
Cites
Siegel, R., Ma, J., Zou, Z., & Jemal, A. (2014) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21208 · Cited by 11,499
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
Self-citationGefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810699 · Cited by 8,261
Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer
Soda, M., Choi, Y. L., Enomoto, M., Takada, S., Yamashita, Y., Ishikawa, S., Fujiwara, S.-I., Watanabe, H., Kurashina, K., Hatanaka, H., et al. (2007) · Nature · doi:10.1038/nature05945 · Cited by 5,439
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
Kwak, E. L., Bang, Y., Camidge, D. R., Shaw, A. T., Solomon, B., Maki, R. G., Ou, S. I., Dezube, B. J., Janne, P. A., Costa, D. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1006448 · Cited by 4,477
Self-citationPao, W., Miller, V., Zakowski, M., Doherty, J., Politi, K., Sarkaria, I., Singh, B., Heelan, R., Rusch, V., Fulton, L., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405220101 · Cited by 4,338
Self-citationComprehensive genomic characterization of squamous cell lung cancers
The Cancer Genome Atlas Research Network (2012) · Nature · doi:10.1038/nature11404 · Cited by 3,994
Self-citationSequist, L. V., Yang, J. C.-H., Yamamoto, N., O'Byrne, K., Hirsh, V., Mok, T., Geater, S. L., Orlov, S., Tsai, C.-M., Boyer, M., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.44.2806 · Cited by 3,228
Self-citationFirst-Line Crizotinib versus Chemotherapy in ALK -Positive Lung Cancer
Solomon, B. J., Mok, T., Kim, D.-W., Wu, Y.-L., Nakagawa, K., Mekhail, T., Felip, E., Cappuzzo, F., Paolini, J., Usari, T., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1408440 · Cited by 3,190
Flagged first, then by citations
Cited by
Sorted by citations
Items 701–800 of 1,000
Nicholson, A. G., Scagliotti, G. V., Tsao, M., Yatabe, Y., & Travis, W. D. (2022) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2022.07.006 · Cited by 20
When Tissue Is No Longer the Issue: Tissue-Agnostic Cancer Therapy Comes of Age
Luoh, S., & Flaherty, K. T. (2018) · Annals of Internal Medicine · doi:10.7326/m17-2832 · Cited by 20
McDaniels, B. A., Hianik, R. S., Bellcross, C. A., Shaib, W. L., Switchenko, J. M., Dixon, M. D., Meisel, J. L., Gogineni, K., & Pentz, R. D. (2019) · Journal of Cancer Education · doi:10.1007/s13187-019-01535-0 · Cited by 19
Li, H., Liu, T., Sun, Z., & Yang, F. (2020) · Thoracic Cancer · doi:10.1111/1759-7714.13649 · Cited by 19
Osarogiagbon, R. U., Sineshaw, H. M., Lin, C. C., & Jemal, A. (2020) · CHEST Journal · doi:10.1016/j.chest.2020.10.075 · Cited by 19
Wang, L., Liu, X., Liu, Z., Wang, Y., Fan, M., Yin, J., Zhang, Y., Ma, Y., Luo, J., Li, R., et al. (2022) · Scientific Reports · doi:10.1038/s41598-021-03946-w · Cited by 19
Hagio, K., Kikuchi, J., Takada, K., Tanabe, H., Sugiyama, M., Ohhara, Y., Amano, T., Yuki, S., Komatsu, Y., Osawa, T., et al. (2023) · Cancer Science · doi:10.1111/cas.15837 · Cited by 19
Management of Dermatologic Complications of Lung Cancer Therapies
Pugliese, S. B., Neal, J. W., & Kwong, B. Y. (2015) · Current Treatment Options in Oncology · doi:10.1007/s11864-015-0368-y · Cited by 19
Fujiwara, Y., Hamada, A., Mizugaki, H., Aikawa, H., Hata, T., Horinouchi, H., Kanda, S., Goto, Y., Itahashi, K., Nokihara, H., et al. (2016) · Cancer Science · doi:10.1111/cas.12983 · Cited by 19
McCoach, C. E., Bivona, T. G., Blakely, C. M., & Doebele, R. C. (2016) · Clinical Lung Cancer · doi:10.1016/j.cllc.2016.05.025 · Cited by 19
Metastatic lung cancer in the age of targeted therapy: improving long-term survival
Rivero, J. D., Enewold, L., & Thomas, A. (2016) · Translational Lung Cancer Research · doi:10.21037/tlcr.2016.11.08 · Cited by 19
Sequencing Therapy for Genetically Defined Subgroups of Non–Small Cell Lung Cancer
Yu, H. A., Planchard, D., & Lovly, C. M. (2018) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_201331 · Cited by 20
Ryška, A., Buiga, R., Fakirova, A. D., Kern, I., Olszewski, W. T., Plank, L., Seiwerth, S., Tóth, E., Eri, Ž., Thallinger, C., et al. (2018) · The Oncologist · doi:10.1634/theoncologist.2018-0008 · Cited by 19
Basket trials: From tumour gnostic to tumour agnostic drug development
Dittrich, C. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.102082 · Cited by 18
Allele-Specific Role of ERBB2 in the Oncogenic Function of EGFR L861Q in EGFR-Mutant Lung Cancers
Sato, H., Offin, M. D., Kubota, D., Yu, H. A., Wilhelm, C., Toyooka, S., Somwar, R., Kris, M. G., & Ladanyi, M. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.09.019 · Cited by 18
Self-citationKim, J. H., Yoon, S., Lee, K. H., Jang, S. J., Chun, S., & Kim, S. (2021) · Cancer Medicine · doi:10.1002/cam4.3874 · Cited by 19
Recurrent Somatic MAP2K1 Mutations in Papillary Thyroid Cancer and Colorectal Cancer
Bu, R., Siraj, A. K., Masoodi, T., Parvathareddy, S. K., Iqbal, K., Al-Rasheed, M. M., Haqawi, W., Diaz, M., Victoria, I. G., Aldughaither, S. M., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.670423 · Cited by 19
Fernandes, G., Martins, N. A., Moura, C. S., Guimarães, S., Reis, J. P., Justino, A., Pina, M. J., Magalhães, A., Queiroga, H., Machado, J. C., et al. (2021) · Cancers · doi:10.3390/cancers13112707 · Cited by 19
Metabolic Changes in Early-Stage Non–Small Cell Lung Cancer Patients after Surgical Resection
Ahmed, N., Kidane, B., Wang, L., Nugent, Z. J., Moldovan, N., McElrea, A., Shariati‐Ievari, S., Qing, G., Tan, L., Buduhan, G., et al. (2021) · Cancers · doi:10.3390/cancers13123012 · Cited by 19
Li, A., Niu, F., Han, J.-F., Lou, N.-N., Yang, J., Zhang, X., Zhou, Q. H., Xie, Z., Su, J., Zhao, N., et al. (2015) · Lung Cancer · doi:10.1016/j.lungcan.2015.10.021 · Cited by 19
Su, K., Kao, J., Ho, B., Chen, H., Chang, G.-C., Ho, C., & Yu, S. (2016) · Scientific Reports · doi:10.1038/srep30944 · Cited by 19
Self-citationRocca, A., Crinò, L., Braga, L., Salton, F., Ruaro, B., Confalonieri, M., Generali, D., & Confalonieri, P. (2025) · British Journal of Cancer · doi:10.1038/s41416-025-03139-6 · Cited by 24
Treatment of ALK-Rearranged Non-Small Cell Lung Cancer: Recent Progress and Future Directions
Cameron, L., & Solomon, B. (2015) · Drugs · doi:10.1007/s40265-015-0415-9 · Cited by 18
Trials to Overcome Drug Resistance to EGFR and ALK Targeted Therapies – Past, Present, and Future
Spaans, J. N., & Goss, G. D. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00233 · Cited by 19
Li, T., Piperdi, B., Walsh, W. V., Kim, M., Beckett, L. A., Gucalp, R. A., Haigentz, M., Bathini, V. G., Wen, H., Zhou, K., et al. (2016) · Clinical Lung Cancer · doi:10.1016/j.cllc.2016.10.003 · Cited by 18
Tfayli, A., Rafei, H., Mina, A. A., Khalil, M., Fakhreddin, N., Mahfouz, R. A., Hamouri, S., Farhat, F., Salem, Z. M. K., Dbouk, H., et al. (2017) · Europe PMC (PubMed Central) · doi:10.22034/apjcp.2017.18.1.107 · Cited by 18
Loubière, S., Drezet, A., Beau‐Faller, M., Moro‐Sibilot, D., Friard, S., Wislez, M., Blons, H., Daniel, C., Westeel, V., Madroszyk, A., et al. (2018) · European Respiratory Journal · doi:10.1183/13993003.01467-2017 · Cited by 19
Vardarli, A. T., Pelit, L., Aldağ, C., Korba, K., Çelebi, Ç., Dizdaş, T. N., Uzun, U. C., Tayfur, E., Aykut, A., Karakuş, H. S., et al. (2020) · Journal of Breath Research · doi:10.1088/1752-7163/ab739b · Cited by 18
Zhou, H., Zhang, H., Shi, M., Wang, J., Huang, Z., & Shi, J. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106856 · Cited by 18
Baraibar, I., Román, M., Rodríguez‐Remírez, M., López, I., Vilalta, A., Guruceaga, E., Ecay, M., Collantes, M., Lozano, T., Alignani, D., et al. (2020) · Cancers · doi:10.3390/cancers12113169 · Cited by 19
Harvey, M. J., Cunningham, R., Sawchyn, B., Montesion, M., Reddy, P., McBride, A., & Chawla, A. (2021) · JCO Precision Oncology · doi:10.1200/po.20.00540 · Cited by 18
An analysis of research biopsy core variability from over 5000 prospectively collected core samples
Bhamidipati, D., Verma, A., Sui, D., Maru, D. M., Mathew, G., Lang, W., Posadas, J., Hein, J. P., Kopetz, S., Futreal, P. A., et al. (2021) · npj Precision Oncology · doi:10.1038/s41698-021-00234-8 · Cited by 18
Self-citationAguilar, A., Mas, L. A., Enríquez, D., Vallejos, C. S., Gutarra-Vilchez, R. B., & Flores, C. J. (2022) · Cancer Control · doi:10.1177/10732748211068637 · Cited by 18
Chakravarthy, V., Schachner, B. I., Amin, A. G., Reiner, A. S., Yamada, Y. J., Schmitt, A. M., Higginson, D. S., Laufer, I., Bilsky, M. H., & Barzilai, O. (2022) · Neurosurgery · doi:10.1227/neu.0000000000002247 · Cited by 18
Naito, Y., Sunami, K., Kage, H., Komine, K., Amano, T., Imai, M., Koyama, T., Ennishi, D., Kanai, M., Kenmotsu, H., et al. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.45081 · Cited by 18
Navigating patient journey in early diagnosis of lung cancer in India
Biswas, B., Talwar, D., Meshram, P. L., Julka, P. K., Mehta, A., Somashekhar, S. P., Chilukuri, S. C., & Bansal, A. (2022) · Lung India · doi:10.4103/lungindia.lungindia_144_22 · Cited by 18
Clarke, J. M., Wang, X., & Ready, N. (2015) · PubMed Central · doi:10.3978/j.issn.2218-6751.2015.05.03 · Cited by 19
Heong, V. Y. M., Syn, N. L. X., Lee, X. W., Sapari, N. S., Koh, X. Q., Isa, Z. F. A., Lim, J., Lim, D. G. S., Pang, B., Thian, Y. L., et al. (2017) · International Journal of Cancer · doi:10.1002/ijc.31091 · Cited by 18
Thi, A. M., Tin, S. T., McKeage, M. J., & Elwood, M. (2020) · Targeted Oncology · doi:10.1007/s11523-020-00718-w · Cited by 18
Xu, Y., Lin, L., Lv, D., Yan, S., He, S., & Ge, H. (2021) · Tissue and Cell · doi:10.1016/j.tice.2021.101535 · Cited by 18
Okuma, Y., Tanaka, Y., Kamei, T., Hosomi, Y., & Okamura, T. (2015) · OncoTargets and Therapy · doi:10.2147/ott.s83179 · Cited by 19
Thompson, J. C., Fan, R., Black, T. A., Yu, G. H., Savitch, S. L., Chien, A. L., Yee, S. S., Sen, M., Hwang, W., Katz, S. I., et al. (2018) · Lung Cancer · doi:10.1016/j.lungcan.2018.11.020 · Cited by 19
Zebrafish Xenograft Model of Human Lung Cancer for Evaluating Osimertinib Resistance
Li, X., Huang, L., Wu, J., He, M., Zhu, S., Zhan, P., Lv, T., & Song, Y. (2019) · BioMed Research International · doi:10.1155/2019/3129748 · Cited by 18
Validating ROS1 Rearrangements As a Therapeutic Target in Non–Small-Cell Lung Cancer
Solomon, B. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.8334 · Cited by 18
Wang, J., Liu, P., Zhang, R., Xing, B., Chen, G., Han, L., & Yu, J. (2024) · Cell Death and Disease · doi:10.1038/s41419-024-07155-x · Cited by 17
Selective Inhibition of ADAM28 Suppresses Lung Carcinoma Cell Growth and Metastasis
Mochizuki, S., Shimoda, M., Abe, H., Miyamae, Y., Kuramoto, J., Aramaki‐Hattori, N., Ishii, K. J., Ueno, H., Miyakoshi, A., Kojoh, K., et al. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-1198 · Cited by 17
Luo, X., Zhou, Z., Zeng, X., Peng, L., & Liu, Q. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2022.985834 · Cited by 20
Combatting acquired resistance to osimertinib in EGFR-mutant lung cancer
Lee, J., Piotrowska, Z., Soo, R. A., Cho, B. C., & Lim, S. M. (2022) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359221144099 · Cited by 17
Xuzhang, W., Huang, H., Yu, Y., Shen, L., Li, Z., & Lü, S. (2023) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359231156387 · Cited by 17
Targeted therapies in non-small cell lung cancer: present and future
McLaughlin, J., Berkman, J. D., & Nana-Sinkam, P. S. (2023) · Faculty Reviews · doi:10.12703/r/12-22 · Cited by 22
Genetic changes of non-small cell lung cancer under neoadjuvant therapy
Warth, A., Endris, V., Stenzinger, A., Penzel, R., Harms, A., Duell, T., Abdollahi, A., Lindner, M., Schirmacher, P., Muley, T., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.8858 · Cited by 17
Driver mutations of young lung adenocarcinoma patients with malignant pleural effusion
Wu, S., Liu, Y., Yu, C., Yang, J. C., & Shih, J. (2018) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22647 · Cited by 18
Mutational landscape and clonal diversity of pulmonary adenoid cystic carcinoma
Li, M., Zhao, B., Liu, S., An, J., Deng, P., Han‐Zhang, H., Ye, J., Mao, X., Chuai, S., & Hu, C. (2018) · Cancer Biology & Therapy · doi:10.1080/15384047.2018.1480296 · Cited by 18
Myall, N. J., Henry, A. S., Wood, D., Neal, J. W., Han, S. S., Padda, S. K., & Wakelee, H. A. (2018) · Clinical Lung Cancer · doi:10.1016/j.cllc.2018.10.003 · Cited by 17
Horn, L., Bauml, J. M., Forde, P. M., Davis, K. L., Myall, N. J., Sasané, M., Dalal, A. A., Culver, K., Wozniak, A. J., Baik, C. S., et al. (2018) · Lung Cancer · doi:10.1016/j.lungcan.2018.12.003 · Cited by 17
Self-citationSafety and Tolerability of Anaplastic Lymphoma Kinase Inhibitors in Non-Small-Cell Lung Cancer
Rocco, D., Battiloro, C., Gravara, L. D., & Gridelli, C. (2019) · Drug Safety · doi:10.1007/s40264-018-0771-y · Cited by 17
Jiang, S. X., Walton, R. N., Hueniken, K., Baek, J., McCartney, A., Labbé, C., Smith, E. C., Chan, S. W. S., Chen, R., Brown, C., et al. (2019) · Cancer Medicine · doi:10.1002/cam4.2603 · Cited by 17
Chiang, C., Huang, H.-C., Shen, C., Luo, Y., Chen, Y., & Chiu, C. (2020) · Targeted Oncology · doi:10.1007/s11523-020-00737-7 · Cited by 17
Zhu, J., Yang, Q., & Xu, W. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13091500 · Cited by 17
Yeung, K. T., More, S., Woodward, B. D., Velculescu, V. E., & Husain, H. (2017) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-017-0260-5 · Cited by 16
EGFR mutations subset in Chinese lung squamous cell carcinoma patients
Sun, Y., Yin, X. H., Wen, M., Zhang, J., Wang, X., Xia, J., Zhang, Y., Zhang, Z., & Li, X. (2018) · Molecular Medicine Reports · doi:10.3892/mmr.2018.8859 · Cited by 19
Novel clinical trial designs emerging from the molecular reclassification of cancer
Nikanjam, M., Kato, S., Allen, T., Sicklick, J. K., & Kurzrock, R. (2025) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21880 · Cited by 21
Pelosi, G., Pellegrinelli, A., Fabbri, A., Tamborini, E., Perrone, F., Settanni, G., Busico, A., Picciani, B., Testi, M. A., Militti, L., et al. (2016) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-016-1931-z · Cited by 16
Ahlborn, L. B., Tuxen, I. V., Mouliere, F. C., Kinalis, S., Schmidt, A. Y., Rohrberg, K. S., Santoni‐Rugiu, E., Nielsen, F. C., Lassen, U., Yde, C. W., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.25948 · Cited by 16
Treatment of oncogene-driven non-small cell lung cancer
Kastelijn, E. A., Langen, A. J. D., & Peters, B. J. M. (2019) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000000572 · Cited by 16
The development of amivantamab for the treatment of non-small cell lung cancer
Brazel, D., & Nagasaka, M. (2023) · Respiratory Research · doi:10.1186/s12931-023-02558-4 · Cited by 19
Vavalà, T., Follador, A., Tiseo, M., Galetta, D., Morabito, A., Maïo, M. D., Martelli, O., Caffo, O., Piovano, P. L., Cortinovis, D. L., et al. (2016) · Lung Cancer · doi:10.1016/j.lungcan.2016.02.011 · Cited by 16
Chen, Y.-L., Lee, C., Lu, C.-C., Yang, S.-C., Chen, W.-L., Lee, Y.-C., Yang, C.-H., Peng, S.-L., Su, W., Chow, N.-H., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0158125 · Cited by 16
Pailler, E., Faugeroux, V., Oulhen, M., Catelain, C., & Farace, F. (2017) · Translational Lung Cancer Research · doi:10.21037/tlcr.2017.07.01 · Cited by 16
Frequency and types of EGFR mutations in Moroccan patients with non–small cell lung cancer
Sow, M. L., Yacoubi, H. E., Moukafih, B., Baldé, S., Akimana, G., Najem, S., Khoyaali, S., Abahssain, H., Chaibi, A., Khan, S. Z., et al. (2020) · Tumori Journal · doi:10.1177/0300891620964571 · Cited by 16
Yang, G., Hao, X., Hu, J., Dong, K., Xu, H., Yang, L., Zhang, S., Yang, Y., Xu, F., Li, J., et al. (2021) · Journal of the National Cancer Center · doi:10.1016/j.jncc.2021.08.001 · Cited by 15
Chen, J., Chen, Y., Liu, L., Jin, X., Shen, Z., Chen, W., Yang, T., Xu, S., Wang, G., Cheng, Y., et al. (2021) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.17094 · Cited by 17
Huang, Y.-H., Hsu, K.-H., Tseng, J., Yang, T., Chen, K., Su, K., Yu, S., Chen, J. J. W., & Chang, G. (2022) · Targeted Oncology · doi:10.1007/s11523-022-00878-x · Cited by 18
Zhu, L., Wang, Y., Yuan, X., Ma, Y., Zhang, T., Zhou, F., & Yu, G. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.1085700 · Cited by 16
Beyond Single-Nucleotide Polymorphisms
Meyer, N. J. (2014) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2014.08.006 · Cited by 16
Zhou, F., & Zhou, C. (2015) · 癌症：英文版 · doi:10.1186/s40880-015-0036-4 · Cited by 17
Nicoś, M., Krawczyk, P. A., Jarosz, B., Sawicki, M., Szumiło, J., Trojanowski, T., & Milanowski, J. (2015) · Clinical and Experimental Medicine · doi:10.1007/s10238-015-0349-2 · Cited by 16
Xu, J., Zhang, X., Yang, H., Ding, G., Jin, B., Lou, Y., Zhang, Y., Wang, H., & Han, B. (2016) · Oncotarget · doi:10.18632/oncotarget.12035 · Cited by 16
Alectinib for Treatment of ALK -Positive Non-Small-Cell Lung Cancer
Avrillon, V., & Pérol, M. (2016) · Future Oncology · doi:10.2217/fon-2016-0386 · Cited by 18
Majmundar, N. J., Shao, B., & Assina, R. (2018) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2018.03.030 · Cited by 16
McKeage, M. J., Tin, S. T., Khwaounjoo, P., Sheath, K. L., Dixon‐McIver, A., Ng, D., Sullivan, R., Cameron, L., Shepherd, P., Laking, G. R., et al. (2019) · Internal Medicine Journal · doi:10.1111/imj.14435 · Cited by 16
Lung and Abdominal Biopsies in the Age of Precision Medicine
Dalag, L., Fergus, J., & Zangan, S. M. (2019) · Seminars in Interventional Radiology · doi:10.1055/s-0039-1693121 · Cited by 16
Treatment of KRAS-Mutant Non–Small Cell Lung Cancer
Kaufman, J. M., & Stinchcombe, T. E. (2017) · JAMA · doi:10.1001/jama.2017.3436 · Cited by 16
Osarogiagbon, R. U., Rami–Porta, R., Tsao, M., Montuenga, L. M., Nishimura, K. K., Giroux, D. J., Travis, W. D., Asamura, H., Rusch, V. W., Carbone, D. P., et al. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.03.003 · Cited by 16
Lung cancer as a paradigm for precision oncology in solid tumours
Schallenberg, S., Merkelbach‐Bruse, S., & Buettner, R. (2017) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-017-2183-2 · Cited by 17
Chang, W., Yen, M., Hung, J., Yang, C., Jian, S., Yeh, I., Liu, K., Hsu, Y., & Kuo, P. (2017) · Oncology Reports · doi:10.3892/or.2017.6141 · Cited by 15
Suda, K., Murakami, I., Obata, K., Sakai, K., Fujino, T., Koga, T., Ohara, S., Hamada, A., Soh, J., Nishio, K., et al. (2020) · Lung Cancer · doi:10.1016/j.lungcan.2020.08.010 · Cited by 15
Maharjan, M., Tanvir, R. B., Chowdhury, K., Duan, W., & Mondal, A. M. (2020) · BMC Bioinformatics · doi:10.1186/s12859-020-3524-8 · Cited by 15
Fang, X., Yu, S., Jiang, Y., Xiang, Y., & Lu, K. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1027664 · Cited by 16
Niimura, T., Miyata, K., Hamano, H., Nounin, Y., Unten, H., Yoshino, M., Mitsuboshi, S., Aizawa, F., Yagi, K., Koyama, T., et al. (2023) · Drug Safety · doi:10.1007/s40264-023-01300-9 · Cited by 16
Yu, L., Xu, J., Qiao, R., Zhong, H., Brueckl, W. M., & Zhong, R. (2023) · Translational Lung Cancer Research · doi:10.21037/tlcr-23-260 · Cited by 15
Yoshida, T., Kumagai, T., Toyozawa, R., Katayama, R., Nishio, M., Seto, T., Goto, K., Yamamoto, N., Ohe, Y., Kudou, K., et al. (2023) · Cancer Science · doi:10.1111/cas.15888 · Cited by 14
ORTIZ-JAIMES, G. E., & Reisenauer, J. S. (2023) · Pragmatic and Observational Research · doi:10.2147/por.s395806 · Cited by 15
Shang, B., Lu, F., Jiang, S., Xing, M., Mao, X., Yang, G., & Zhang, H. (2023) · Aging · doi:10.18632/aging.205038 · Cited by 15
Molecular and clinical implementations of ovarian cancer mouse avatar models.
Zayed, A. A., Mandrekar, S. J., & Haluska, P. (2015) · PubMed · doi:10.3978/j.issn.2304-3865.2015.04.01 · Cited by 15
Sequencing of ALK Inhibitors in ALK+ Non-Small Cell Lung Cancer
Gadgeel, S. M. (2017) · Current Treatment Options in Oncology · doi:10.1007/s11864-017-0479-8 · Cited by 15
Liu, D., Xu, W., Ding, X., Yang, Y., Su, B., & Fei, K. (2017) · Journal of Cancer · doi:10.7150/jca.21151 · Cited by 15
Somatic mutations and immune checkpoint biomarkers
Parris, B. A., Shaw, E., Pang, B., Soong, R., Fong, K. M., & Soo, R. A. (2019) · Respirology · doi:10.1111/resp.13463 · Cited by 15
Pan, Z., Wang, K., Chen, Q., Zheng, X., Song, Z., & Ding, X. (2019) · Journal of Cancer · doi:10.7150/jca.32989 · Cited by 15
Tamiya, A., Koh, Y., Isa, S., Kubo, A., Ando, M., Saka, H., Yoshimoto, N., Takeo, S., Adachi, H., Tagawa, T., et al. (2020) · Cancer Medicine · doi:10.1002/cam4.2897 · Cited by 16
Metadata
- Authors
- Kris, M. G., Johnson, B. E., Berry, L. D., Kwiatkowski, D. J., Iafrate, A. J., Wistuba, I. I., Varella-Garcia, M., Franklin, W. A., Aronson, S. L., Su, P.-F., Shyr, Y., Camidge, D. R., Sequist, L. V., Glisson, B. S., Khuri, F. R., Garon, E. B., Pao, W., Rudin, C., Schiller, J., Haura, E. B., Socinski, M., Shirai, K., Chen, H., Giaccone, G., Ladanyi, M., Kugler, K., Minna, J. D., & Bunn, P. A.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- Dana-Farber Cancer Institute (US)
- Vanderbilt University (US)
- Brigham and Women's Hospital (US)
- Massachusetts General Hospital (US)
- The University of Texas MD Anderson Cancer Center (US)
- University of Colorado Cancer Center Denver, Aurora
- University of Colorado Cancer Center (US)
- The Partners HealthCare Center for Personalized Genetic Medicine, Boston, Massachusetts
- Winship Cancer Institute (US)
- University of California, Los Angeles (US)
- Johns Hopkins University (US)
- The University of Texas Southwestern Medical Center (US)
- Moffitt Cancer Center (US)
- UPMC Hillman Cancer Center (US)
- Medical University of South Carolina (US)
- National Institutes of Health (US)
- Corresponding author
- Kris, Mark G.
- ORCID
- Kris, Mark G.
- Johnson, Bruce E.
- Berry, Lynne D.
- Kwiatkowski, David J.
- Iafrate, A. John
- Wistuba, Ignacio I.
- Shyr, Yu
- Camidge, D. Ross
- Sequist, Lecia V.
- Glisson, Bonnie S.
- Khuri, Fadlo R.
- Garon, Edward B.
- Pao, William
- Rudin, Charles
- Schiller, Joan
- Haura, Eric B.
- Socinski, Mark
- Shirai, Keisuke
- Chen, Heidi
- Giaccone, Giuseppe
- Ladanyi, Marc
- Minna, John D.
- Bunn, Paul A.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2014-05-21
- Volume
- 311
- Issue
- 19
- Pages
- 1998
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- PMC
- PMC4163053
- OpenAlex
- W2065477010
- Semantic Scholar
- 07fff1c9d77fb2b8731d7d86b38c7ac05df654c7
- Cited by
- 1,724
- References
- 69
- Citations by year
- 2026: 55 · 2025: 99 · 2024: 101 · 2023: 116 · 2022: 164 · 2021: 171 · 2020: 173 · 2019: 137 · 2018: 186 · 2017: 162 · 2016: 173 · 2015: 146 · 2014: 37
- FWCI
- 138.25
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- JAMA (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (UL1TR000124)
- National Cancer Institute (RC2CA148394, K23CA149079, P01CA129243, 1RC2CA148394‐010, P50CA058187, P30CA008748, P30CA016672, P30CA046934)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
- Keywords
- lung adenocarcinoma, oncogenic drivers, targeted therapy, multiplex genotyping, KRAS, EGFR, ALK rearrangement, BRAF, PIK3CA, ERBB2, MET amplification, NRAS, MEK1, AKT1, metastatic lung cancer, survival, genotype-directed therapy, clinical trial recruitment
- MeSH terms
- Adenocarcinoma of Lung, Adenocarcinoma, Aged, Female, Genotype, Humans, Lung Neoplasms, Male, Middle Aged, Proto-Oncogenes, Survival Analysis, Sequence Analysis, DNA, Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization, Molecular Targeted Therapy, Multiplex Polymerase Chain Reaction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-06, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-06 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
